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Abstract
Tetrathiomolybdate (TM) is a potent nontoxic orally
delivered copper complexing agent under development
for the last several years for the treatment of Wilson’s
disease. It has been shown to block angiogenesis in
primary and metastatic tumors. Therefore, the combi-
nation of cytotoxic radiotherapy (RT) and antiangio-
genic TM could target both the existing tumor and the
tumor microvasculature in a comprehensive strategy.
Using a Lewis lung high metastatic (LLHM) carcinoma
mouse tumor model, we demonstrate that the combina-
tion of TM and RT is more effective than either used as
monotherapy. We also show that their therapeutic
effects are additive, with no additional toxicity. We show
that TM has no significant cytotoxicity in vitro against
LLHM tumor cells, further supporting the antiangiogenic
mechanism for its action.
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Introduction
The tumor microvasculature can serve as an excellent target
for the treatment of all types of tumors [1,2 ]. Compounds
that interfere with critical steps in the angiogenic cascade are
making their way into the clinical arena as potential
treatment options for patients with cancer [3,4 ]. The steps
required for successful tumor angiogenesis are diverse and
depend on an imbalance [5,6] between angiogenesis activa-
tors such as vascular endothelial growth factor (VEGF) [7],
basic fibroblast growth factor (bFGF) [8-11], and trans-
forming growth factor -beta (TGF-beta) [12], and inhibitors
such as thrombospondin 1 [13], angiostatin [14], and
endostatin [15]. In tumors, this imbalance serves to tilt the
angiogenic switch in favor of angiogenesis and is thought to
be important in regulating both primary and metastatic tumor
growth [6].
A strategy that affects multiple activators of angiogenesis
may be highly applicable for the treatment of human tumors
and could potentially suppress tumor angiogenesis more
powerfully than single target strategies. Copper is a required
cofactor for the function of many key mediators of angio-
genesis including bFGF [16-19], VEGF and angiogenin
[20,21]. Several animal studies have demonstrated that
copper is required for angiogenesis [22,23]. Studies in
animal models using the copper chelator penicillamine and
a low copper diet reported a decrease in tumor size relative to
controls [23,24]. In two animal models, a VX2 carcinoma
implanted in the brains of rabbits and a 9L gliosarcoma
implanted in the brains of rats, copper chelation was shown to
inhibit both angiogenesis and tumor growth [25,26].
Tetrathiomolybdate (TM) is a copper reducing agent
used in the treatment of Wilson’s disease [27], an
autosomal recessive disorder of copper transport that
results in abnormal copper accumulation primarily in the
liver and brain. There is extensive clinical experience with
TM as a copper- lowering drug in the treatment of Wilson’s
disease [27]. TM is the most potent copper-binding agent
known, forming a stable tripartite complex with copper and
protein. When given with food, TM complexes dietary copper
with food protein and prevents absorption of copper from the
gastrointestinal tract. When given between meals, TM is
absorbed into the blood stream where it complexes with free
(or loosely bound) copper and serum albumin. This TM-
bound copper fraction is no longer available for cellular
uptake, has no biologic activity, and is slowly cleared from
the body in bile and urine. Thus, patients taking TM are
placed in a negative copper balance immediately. The best
measure of the level of biologically active copper in the body
is obtained by the measurement of the protein ceruloplasmin
(Cp) [28], a protein made by the liver in amounts that
directly reflect the level of biologically active copper present
in the body.
It has recently been shown that TM can impede the
development of mammary tumors in Her2-neu transgenic
mice [29]. The safety and antitumor effects of TM therapy
alone in patients with solid tumors have been evaluated in a
Phase I clinical trial [30]. This phase I trial demonstrated that
TM could modulate copper stores to impair angiogenesis, but
Neoplasia . Vol. 4, No. 2, 2002, pp. 164 –170
www.nature.com/neo
164
Abbreviations: Cp, ceruloplasmin; MTT, ( 3 - 4,5 - dimethlythiazol - 2yl ) - 2,5 diphenyltetra-
zolium bromide; bFGF, basic fibroblastic growth factor; LLHM, Lewis lung high metastatic
carcinoma; RT, radiotherapy; TGF - beta, transforming growth factor - beta; TM, tetra-
thiomolybdate; VEGF, vascular endothelial growth factor
Address all correspondence to: Dr. Mohamed Khan, Department of Radiation Oncology,
Division of Radiation and Cancer Biology, University of Michigan Medical Center,
Comprehensive Cancer and Geriatrics Center, 1500 East Medical Center Drive, Room
4304 CCGC, Ann Arbor, MI 48109 - 0936, USA. E -mail: mokhan@umich.edu
Received 8 August 2001; Accepted 22 October 2001.
Copyright# 2002 Nature Publishing Group All rights reserved 1522-8002/02/$25.00
RESEARCH ARTICLE
leave other copper-dependent cellular processes largely
intact, so that no significant clinical toxicity occurred. There
was only a small percentage of grade 1–2 hematologic
toxicity (easily reversible changes in hematocrit or white
count) noted.
Radiotherapy against primary tumors has been shown to
be improved by the addition of antiangiogenic agents using
animal models [31-35]. This has been accomplished without
significant side effects or increased toxicity noted. In this
paper we present preclinical studies that test whether
antiangiogenic therapy with the copper lowering agent TM
can be combined with radiation therapy to improve the
efficiency of the radiotherapy (RT) of primary tumors in mice.
We demonstrate that angiogenic inhibition through copper
reduction can be combined with cytotoxic RT to improve
tumor control.
Materials and Methods
In Vivo Therapy with Radiation or TM
Lewis lung high metastatic (LLHM) carcinoma cells were
derived from Lewis lung low metastatic (LLLM) tumors by
serial passage in C57BL6 mice and selection for lung
metastases that grow with large primary tumors present
( i.e., primary tumors that no longer produce angiostatin,
which inhibits metastatic growth). The LLHM cell line was
maintained by serial passage in C57BL6/J mice (Jackson
Laboratories, Bar Harbor, ME). The phenotype of lung
metastasis was assessed at each passage. Male 6- to 9-
week-old C57BL6/J mice were used for experiments. The
mice were acclimated and caged in groups of five or less and
then were shaved. All mice were fed a diet of animal chow ad
libitum. They were anesthetized using isoflurane delivered
through a ventilation chamber before all procedures and
were observed until fully recovered.
Tumors were isolated from carrier mice and implanted into
experimental animals as previously described [14]. In
summary, animals with 1000-mm3 tumors were sacrificed,
and the skin overlying the tumor cleaned with betadine and
ethanol. In a laminar flow hood, tumor tissue was excised
under aseptic conditions. A suspension of tumor cells in
phosphate-buffered saline (PBS) was made by passage of
viable tumor tissue through a sieve and a series of
sequentially smaller hypodermic needles. The final concen-
tration was adjusted to 1107 cells /ml and the suspension
placed on ice. The subcutaneous dorsa ( for passage) of
carrier mice, or upper leg dorsa ( for radiation experiments),
were injected with 1106 cells in 0.1 ml of PBS after cleaning
the injection site with ethanol.
Initial experiments using 60 mice were carried out to
determine the average volume of water consumed per
mouse per day. The volume of water imbibed in each
24-hour period was measured for each cage, and the
volume per mouse determined. The concentration of TM in
the water bottles was then calculated to deliver the
appropriate dose of TM. Freshly mixed TM was placed into
the water bottles each day.
The mice receiving RT were irradiated with a gamma-cell
40 cesium irradiator (100 cGy/min). The unit has two Cs
sources creating a more homogeneous field between the
sources where the specimen is placed. A specially designed
metal cylindrical jig apparatus was used to immobilize the
mouse with the right ( tumor-bearing) leg/ flank region
extended. The jig was placed into a cylindrical lead shield
encasing the bodies of the mice while exposing the leg/ flank
tumor to be irradiated. No anesthesia was necessary.
Measurements demonstrate that the exposed leg receives
the full dose of RT, whereas the shielded body receives <2%
of the total dose given.
Copper Status of Mice
Blood was collected from mice treated with TM by
anesthetizing the mice with isoflurane and performing
cardiac puncture. The blood was centrifuged at 3000g,
48C, and the serum collected and frozen at 208C until the
assays were run.
The Cp levels were measured as per a standard assay
[36]. Twenty- five microliters of serum from an individual
mouse were placed into each of two tubes and 375 l of
0.1 M sodium acetate buffer (pH 5.0, stored at 48C) was
immediately added. Tubes were placed in a 308C water
bath. After 5 minutes, 100 l of o -dianisidine dihydrochloride
(7.88 mM, Sigma, St. Louis, MO) reagent (preincubated at
308C) was pipetted into each tube. After 30 minutes one of
the two tubes for each group was removed from the water
bath, and 1 ml of 9 M sulfuric acid was added to quench the
reaction. After 45 minutes, the second tube was quenched
and the absorbency of both tubes at 540 nm was analyzed
using a 1-cm path length cuvette in a spectrophotometer.
The Cp concentration in international units was calculated by
the formula: Cp oxidase activity=(A45A30)0.625 U/ml.
Microvessel Density Counting
Tumors were preserved in 10% neutral buffered formalin,
and embedded in paraffin. Five-micrometer sections were
immunohistochemically stained for CD31. In summary: The
sections were deparaffinized (xylene and then ethanol ), and
then hydrated with water. They were placed in 1% hydrogen
peroxide in methanol for 30 minutes at room temperature.
The sections were washed with double-distilled water, and
then Tris buffer (pH 7.2) for 5 minutes. Next, they were
treated with proteinase K 36 g/ml) in 0.2 M Tris buffer (pH
7.2) at 378C for 30 minutes, and then were washed in Tris
buffer (pH 7.2), 5 minutes. The sections were then blocked
in TNB buffer (0.1M Tris -HCl pH 7.5, 0.15 M NaCl, 0.5%
blocking reagent), 30 minutes at room temperature (TSA-
Indirect kit, NEN Life Science Products, Boston, MA). The
primary antibody ( rat anti -mouse CD31, Pharmingen, San
Diego, CA) was added at 1:250 dilution in TNB buffer
overnight at 48C. They were then rinsed with TNT wash
buffer (NEN TSA-Indirect kit 0.1M Tris-HCl pH 7.5, 0.15 M
NaCl, 0.05% Tween–20). Secondary antibody was then
added (biotinylated rabbit anti - rat, Vector #BA-4001) at a
1:200 dilution in TNB buffer for 30 minutes at room
temperature. They were then rinsed with TNT buffer, and
Neoplasia . Vol. 4, No. 2, 2002
Radiotherapy and Antiangiogenic TM in Lung Cancer Khan et al. 165
incubated in streptavidin horseradish peroxidase (SA-
HRP), at a 1:100 dilution in TNB buffer for 30 minutes at
room temperature, and then washed again. Biotinylated
tyramide in the amplification diluent was added for 7 minutes
at room temperature, and washes done. Incubation in SA-
HRP in 1:100 TNB for 30 minutes at room temperature was
done and washes carried out. DAB was then added, and the
slides were counterstained. Hot spots were counted as
previously described [37]. The slides were viewed at 100
magnification to determine ‘‘hot spots’’ of angiogenesis, and
the vessels present were counted. Generally, five of these
were counted per mouse sample. Two different investigators
did the counting (M.K.K. and N.K.G.), and the values were
averaged.
In Vitro Tumor Cell Proliferation Assay (MTT Assay)
In vitro experiments were carried out on the LLHM tumor
cell line, using an MTT (3- (4,5-dimethylthiazol -2yl ) -2,5
diphenyltetrazolium bromide, Sigma) proliferation assay.
MTT stains live cells, and the A595 absorbency correlates
with cell number. TM was added to the LLHM cells at
concentrations of 0, 0.001, 0.01, 0.1, 1, or 10 nM. The
proliferation was carried out for 5 days with daily measure-
ments of absorbency. A flat -bottomed 96-well Falcon
microtest tissue culture plate was used for each time point
with six replicate wells used for each TM concentration. One
thousand cells were added to each well. TM was added to
bring the concentration to 0, 0.001, 0.02, 0.01, 0.0.1, 1.0, and
10 nM per well. On days 0 to 4, 50 l of MTT was added
to each well using a repeat pipetter and the plate was incu-
bated for 2 hours at 378C. The plates were centrifuged for
5 minutes at 2200 rpm in a 48C Sorvall RT 6000B centrifuge.
One hundred microliters of dimethyl sulfoxide was added to
each well using a repeat pipetter and the plate agitated for
5–10 minutes. The absorbency at 595 nm was read by a
Dynatek MR 5000 plate reader. An absorbency titration
curve was generated using the MTT assay carried out with
10- fold increases in cells from 0 to 1 million cells and the
absorbency at 595 nm measured.
Statistical Methods
The tumor volume measurements were analyzed using
growth curve random effects models. The model was fit to
the logarithm of the tumor size measurements between 10
and 16 days after subtracting the logarithm of the baseline
volume. The models allowed for an exponential growth of the
tumors and the evaluation of the difference between treat-
ments. The method gave estimates of the treatment effects
and interactions between the treatments. Each of the four
experiments was analyzed separately and in a combined
analysis that allowed for differences in growth rate and
intercept between the experiments. A repeated measures
mixed model was applied to tumor values to analyze tumor
growth.
Kaplan–Meier plots and Cox proportional hazards mod-
els were used to compare the survival times in the first
16 days of the four treatment groups. Deaths after 16 days
were reclassified as censored at 16 days due to the rapid
onset of death due to lung metastases after 16 days
particularly in the untreated control group. For the Cox
model, the experiment number was included as a baseline
hazard stratification variable, and log of initial tumor volume
and treatment group were the covariates. Likelihood ratio
tests were used to test the null hypothesis that the four
treatment groups gave equal survival after adjusting for initial
tumor volume and experiment number.
Results
In Vivo TM and Radiotherapy Experiments
One million cells were injected into the flanks of C57BL6
mice, and the tumors grown to an average of 291 mm3
(212±53, 288±82, 305±68, and 359±113 mm3 in experi-
ments 1 to 4, respectively ). In each experiment the tumor
volumes were kept to within 20% of the mean volume on day
zero. The mice were then separated into four groups and
treated as follows: (a) no therapy, (b) TM alone, (c) RT
alone, (d) TM+RT. TM was continued for the duration of the
experiment in groups b and d. Radiotherapy was delivered to
all of the tumors in groups c and d on the same day when the
tumors reached an average of 522 mm3 (493±76, 523±117,
520±160, and 552±236 mm3 in experiments 1 to 4,
respectively). Mice were observed clinically for any evidence
of copper reduction toxicity, and the dose of TMwas adjusted
as needed throughout the experiment. A dose of 15 Gy was
selected for RT, as this dose was shown in previous
experiments (data not shown) to inhibit tumor growth but
not produce cures. If the tumors are cured, there is no way to
assess interaction with another agent, and if too little dose is
given, the growth curves would look too much like the
untreated arm. The dose of 15 Gy, therefore, permitted
analysis of the interaction of RT and TM.
The total number of mice in experiments 1 to 4 at the
beginning of each experiment was (a) 38 mice in the
untreated group, (b) 38 mice in the TM alone group, (c) 35
mice in the RT alone group, and 35 mice in the RT+TM
group. The exact number of mice in each arm of each
experiment over time is shown in Figure 1. In experiment 1,
the mice received 0.75 mg/mouse per day of TM orally for
15 days, then 0.5 mg/mouse per day for the duration of the
experiment. In experiments 2–4, they received 1 mg/mouse
per day of TM orally for 2 days, then 0.5 mg/mouse per day
for the duration of the experiment. The effectiveness of the
TM doses was assessed by measuring the copper chelation
status (reflected in the Cp levels) shown below.
The statistical analysis was performed using a growth
curve random effects model between 10 and 16 days. Figure
1 shows the tumor growth data, plots of log volume change
from baseline versus time, for four separate experiments.
The relative difference between the tumor volumes in the
period 10–16 days was similar across the four experiments.
In all the experiments, there was a significant treatment
effect (P<0.001 for all four experiments). The analysis of the
combined data shows the decrease in tumor volume
compared to control in the period 10–16 days (Table 1).
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The effect of RT and TM appeared to be close to additive
on the scale of the logarithm of tumor volume. In experiments
2 and 4 there was a weak suggestion of subadditivity,
whereas in experiment 3 there was a suggestion of super-
additivity. Overall there was no statistically significant
interaction between TM and RT for any of the experiments
(P=0.27 for experiment 2, P=0.06 for experiment 3, and
P=0.16 for experiment 4). This indicates that the effects of
TM and RT are at least additive with no definite evidence of
synergy.
There was no increased toxicity ( retraction, ulceration, or
death) in the mice receiving TM+RT compared to mice
receiving either therapy alone. The most common clinical
signs of TM toxicity occurred when themice did not drink, and
they then appeared dehydrated (decreased skin turgor, hair
Figure 1. The logarithm of the initialized tumor volumes versus the days of treatment are shown for four experiments. Onemillion LLHM tumor cells were injected into
the flanks of mice and grown to an average of 291 mm3 ( tumor volumes were calculated by 0.52lw2. At this point the mice were sorted into their respective
groups, and started on TM if appropriate. When themice in the RT or RT+TM groups reached an average of 522mm3 (2 days later ) they all received RT on the same
day to the tumor - injected flanks using a gamma -cell Cs irradiator and specially designed shielding. The number of mice still living are shown for all time points.
Statistical analysis was done from days 10–16. The y axis represents the logarithm of the tumor volumes initialized for the starting tumor volume on day 0. All mice
getting TM began on day 0. In experiment 1, they received 0.75 mg /mouse per day of TM orally for 15 days, then 0.5 mg /mouse per day for the duration of the
experiment. In experiments 2–4, they received 1 mg /mouse per day of TM orally for 2 days, then 0.5 mg /mouse per day for the duration of the experiment.
Table 1. Analysis of the Combined Tumor Growth Data.
Treatment Ratio of Tumor Volume Compared to
Untreated Control on Days 10–16
(95% Confidence Interval )
Untreated control 1
TM 0.55 (0.47, 0.64 )
RT 0.34 (0.20, 0.41 )
TM+RT 0.22 (0.19, 0.26 )
A comparison of the combined tumor growth data from all four experiments
and for the day 10–16 time period demonstrated the relative differences
shown. All tumor volumes are shown relative to the untreated controls.
Figure 2. Cp assay. Serum Cp levels (as represented by the average
absorbency at 540 -nm wavelength ) were measured at various time points in
TM- treated tumor - bearing mice. Each point represents an average measure-
ment of at least two mice. As a comparison, the top curve ( labeled untreated )
represents the baseline measurement of Cp from five tumor - bearing
untreated mice.
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with ruffled appearance, and eventually lessmovement and a
hunched-over posture). The mice were assessed through-
out the experiment to note any differences in fibrosis or
swelling or infection in the radiation field with none apparent.
An analysis of survival revealed that 42 of the 146 animals
died by day 16. The initial tumor volume was highly
statistically significantly associated with survival time
(P=0.006). There were significant differences between the
four treatment groups (P=0.03). The estimated relative
hazard and 95% confidence intervals relative to the control
group were 0.59 (0.22, 1.58) for TM, 1.62 (0.72, 3.70) for RT
and 0.50 (0.19, 1.32) for TM+RT. Thus, there is marginal
evidence that the addition of TM may improve the survival of
these animals.
Copper Status
Figure 2 shows the Cp levels measured in experiments 2,
3, and 4. Each Cp level is the average of measurements from
the sera of at least two mice. The average Cp levels of mice
measured in experiments 2, 3, and 4 were 0.028 U/ml
( range 0.018–0.037), 0.077 U/ml ( range 0.063–0.086),
and 0.019 U/ml ( range 0.005–0.032), respectively. The
average Cp level of untreated tumor-bearingmice was found
to be 0.129 U/ml ( range 0.102–0.147). Reduction of copper
levels was obtained in these experiments and to the level
previously demonstrated to inhibit tumor growth in mice and
humans [29,30]. In the mice, copper reduction could be
obtained within 2 days, and the Cp was reduced to target
levels by the time the radiation was delivered.
Microvessel Density Counting of Tumors
Microvessel density at day 2 of TM therapy indicated a
trend for decreased microvessel density in the TM-treated
tumors, but it did not reach statistical significance (Figure
3A ). There was no difference in microvessel density
between the untreated, RT alone, TM alone, and RT+TM
samples at the end of the experiment on day 16 (Figure 3B ).
Microvessel density counting has been shown to have
prognostic significance in numerous studies. However,
recent studies are seriously calling into question the ability
of microvessel density to correlate with response to therapy
(Lynn Hlatky, personal communication). The density is
dependent on the number of microvessels and on the
number of tumor cells in a given field. Although initially there
may be a difference in microvessel density between the
treated and control groups, as the antiangiogenic factors
Figure 3. Microvessel density counting of mouse tumors. The chart in (A )
shows a trend for TM- treated tumors to have decreased microvessel density
counts. The difference is not statistically significant as demonstrated by the
overlapping standard deviation error bars. In (B ) the average microvessel
density counts for untreated, RT - treated, TM- treated, and RT+TM– treated
tumors show not statistically significant differences. Each bar represents the
average microvessel counts at 200 magnification from three mice (with two
to five hot spots counted per mouse tumor ), and with two independent
investigators counting. The same results occur for when the data for each
investigator are analyzed separately ( data not shown ).
Figure 4. MTT assay in vitro tumor cell proliferation analyses were carried out
on LLHM tumor cells from day 0 to day 4. The y axis absorbency values are
proportional to the number of tumor cells. Each color represents a different
concentration of TM ( ranging from 0 to 10 nM) being added to the LLHM cells.
Each bar represents the average of five microtiter well values. The error bars
represent standard error. There is no statistically significant difference in
tumor cell number noted at any time point and at any concentration of TM.
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take effect, and the tumor cell growth slows down or
apoptosis ensues, the density can change to a higher value
as the relative number of microvessels to tumor cells
increases.
Effects of TM Concentration on LLHM Proliferation In Vitro
We carried out MTT assays on the LLHM tumor cell line to
determine whether escalating concentrations of TM would
effect tumor growth in vitro. There was no statistically
significant difference at any TM concentration. Figure 4
shows the growth curve of the tumor cells with varying
concentrations of TM (0.001–10 nM). The physiologic
concentration of TM in human patients is estimated to be
0.01 nM, indicating that there is no change in cancer cell
survival even at 1000 times (10 nM) this concentration of TM
in vitro.
Discussion
The combination of the antiangiogenic copper complexing
agent TM with RT caused a greater decrease in the size of
primary LLHM carcinoma tumors in mice than either used as
monotherapy. In addition, TM had no affect on the
proliferation of LLHM cells in vitro, even at concentrations
of TM 1000- fold over those expected in the tumors. There
was no increased toxicity with the combination therapy
(RT+TM) in these preclinical studies. This is the first report
that the combination of antiangiogenic therapy by copper-
lowering therapy has been demonstrated to have efficacy in
combination with RT to increase the control of tumor growth.
There is a small amount of published data indicating that
copper chelation may help induce apoptosis in tumor cells
treated with DNA-damaging agents like bleomycin. This
would yield a model where copper reduction helps RT (a
DNA-damaging agent) to induce apoptosis in tumor cells
[38,39]. There is also, however, published data indicating
that copper appears to increase tumor kill through oxidative
radical formation (a key mechanism of RT- induced cell
killing), and this would not support the role of copper
reduction in increasing tumor cell kill by RT [40]. We also
demonstrate that copper reduction with TM does not effect
tumor cell proliferation in our in vitro system.
Radiotherapy against primary tumors has been shown to
be improved by the addition of antiangiogenic agents [31-
35]. The work of Teicher et al. is particularly intriguing, as it
demonstrated an increase in the concentration of oxygen
occurs with antiangiogenic therapy [32]. The mechanism for
this is unknown, but there are many postulated possibilities.
We postulate that a significant component of the effect of
RT on tumor growth could be due to the antiangiogenic
effects of RT on the tumor endothelium. Radiotherapy has
been shown to damage endothelial cells (particularly
capillary endothelial cells ) in vivo, and many effects of RT
are postulated to be due to this [41,42]. Radiotherapy could
be acting as a spatially specific antiangiogenic agent. Thus,
when RT is then combined with another antiangiogenic agent
like TM, it is in principle possible to greatly increase the
effects on tumor growth. In theory, one could use a different
dosing (or fractionation) of RT to treat tumor endothelium,
and possibly have a large effect on tumor growth. This would
be analogous to the use of different dosing of chemotherapy
(monotonic dosing) to best treat the tumor endothelium, as
was first done by Browder et al. [43]. The combination of this
new antiangiogenic dosing of chemotherapy with a weak
antiangiogenic agent has also been shown to have at least
an additive effect in long- termmousemodels by Kerbel [44].
It is possible that different RT schedules, or different
methods for specifically targeting the microvasculature with
RT, could disrupt angiogenesis more effectively.
Copper reduction with TM can affect multiple angio-
genesis activators. A strategy that affects multiple activators
of angiogenesis could potentially suppress tumor angio-
genesis more powerfully than single target strategies.
Numerous animal studies demonstrate that copper lowering
is antiangiogenic, and can therefore suppress tumor growth.
TM is an orally delivered copper complexing drug and has
been used successfully for several years in experimental
studies to treat Wilson’s disease in humans. The exact
copper status of patients can be easily and accurately
determined using a simple blood test (Cp). A phase I study
demonstrated that the copper reduction to levels necessary
to inhibit angiogenesis have little toxicity in humans [30]. We
now present preclinical data demonstrating that antiangio-
genic copper lowering with TM can be combined with
cytotoxic (and probably also antiangiogenic) RT, and that
their contributions are additive with respect to tumor control
with no noticeable increase in toxicity. We are currently
developing phase I clinical trials examining the combination
of TM with RT in human cancers at the University of
Michigan.
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